ARTICLE | Company News
CAT, Merck HIV deal
October 10, 2001 7:00 AM UTC
Cambridge Antibody Technology (LSE:CAT; CATG) signed a five-year deal with MRK to develop therapeutics against a target involved in HIV-mediated diseases. CAT will use its human phage antibody librari...